Clinical outcomes of patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma

Table 1 General characteristics of all patients with duodenal adenocarcinoma and intestinal-type papilla of Vater adenocarcinoma included in this study

	Total, n = 155	Duodenum, n = 99	Papilla, n = 56	P value
Age				0.237
Age, median [IQR]	64 [58-73]	63 [56-72]	66 [58-74]
Sex (%)				0.742
Male	94 (60.6)	61 (61.6)	33 (58.9)
ASA (%)				0.852
ASA I	19 (12.3)	12 (12.1)	7 (12.5)
ASA II	83 (53.5)	49 (49.5)	34 (60.7)
ASA III	31 (20.0)	19 (19.2)	12 (21.4)
ASA IV	1 (0.6)	1 (1.0)	0 (0.0)
NR	21 (13.5)	18 (18.2)	3 (5.4)
TNM stage (%)				< 0.001
Stage I	25 (16.1)	7 (7.1)	18 (32.1)
Stage II	26 (16.8)	20 (20.2)	6 (10.7)
Stage III	65 (41.9)	39 (39.4)	26 (46.4)
Stage IV	34 (21.9)	29 (29.3)	5 (8.9)
NR	5 (3.2)	4 (4.0)	1 (1.8)
Treatment (%)
Curative intent	122 (78.7)	71 (71.7)	51 (91.1)	0.003
Surgery	89 (73.0)	43 (60.6)	46 (90.2)
Neoadjuvant + surgery	3 (2.5)	3 (4.2)	0 (0.0)
Surgery + adjuvant therapy	21 (17.2)	17 (23.9)	4 (7.8)
Primary resection + treatment metastasis	9 (7.4)	8 (11.3)	1 (2.0)
Palliative treatment	23 (14.8)	20 (20.2)	3 (5.4)	0.848
Chemotherapy	21 (91.3)	18 (90.0)	3 (100.0)
Radiotherapy	1 (4.3)	1 (5.0)	0 (0.0)
Chemotherapy + radiotherapy	1 (4.3)	1 (5.0)	0 (0.0)
Best-supportive care	8 (5.2)	7 (7.1)	1 (1.8)
NR	2 (1.3)	1 (1.0)	1 (1.8)

Duodenum: Duodenal adenocarcinoma; Papilla: Intestinal-type papilla of Vater Adenocarcinoma; ASA: American Society of Anesthesiologists physical status classification system (ASA-score); TNM: disease stage according to the American Joint Committee on Cancer staging system (AJCC 7^th edition); IQR: Interquartile range; NR: Not reported.